lancet-header
Preprints with The Lancet is part of SSRN´s First Look, a place where journals and other research experts identify content of interest prior to publication. These preprint papers are not peer-reviewed. Authors have either opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet, or submitted directly via SSRN. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These papers should not be used for clinical decision making or reporting of research to a lay audience without indicating that this is preliminary research that has not been peer-reviewed. For more information see the Comment published in The Lancet, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com

Pulmonary Adverse Events of Small Molecule Tyrosine Kinase Inhibitors: Meta-Analysis and Systematic Review

36 Pages Posted: 5 Mar 2019 Last revised: 11 Mar 2019

See all articles by Jun Keng Khoo

Jun Keng Khoo

Alfred Hospital

Hayley Barnes

Alfred Hospital

Seraphina Key

Monash University - Central Clinical School

Ian N. Glaspole

Alfred Hospital; Monash University - Central Clinical School

Andrew Ostor

Monash University - Central Clinical School; Cabrini Medical Centre

More...

Multiple version iconThere are 2 versions of this paper

Abstract

Background Small molecule tyrosine kinase inhibitors (smTKI) are signalling molecules, which modulate the cytokine receptor-mediated intracellular signal cascade, and is an effective treatment for several autoimmune diseases and malignancies. As smTKI are novel, long-term safety is uncertain. Commonly reported side effects include infections, typically pulmonary and herpes zoster. As published data mainly examines tofacitinib trials, the class effect of smTKI is unknown. Methods We performed a meta-analysis of all published trial data on the pulmonary adverse effects of smTKIs. EMBASE, MEDLINE, and CENTRAL databases were searched up to September 2018 for randomized controlled trials, observational studies, case reports, and post marketing surveillance, comparing any smTKI with placebo or another therapy, or as monotherapy at different doses. Primary outcomes comprised of any respiratory complications including upper and lower respiratory tract infections, influenza, opportunistic respiratory infections, pneumonia, interstitial pneumonitis, pulmonary embolism, and lung neoplasm. Findings We identified 2253 citations for screening, and selected 150 for full text review. Seventy-five studies were analyzed, including 49 RCTs, 16 observational studies, three case reports, and seven post-marketing surveillance studies, comprising 153,942 participants. Median duration of RCTs was 24 weeks. The overall risk of any pulmonary adverse event with smTKI is low across RCTs and observational studies. There was significantly increased risk of developing upper respiratory tract infections (URTI) (RD 0·03, 95% CI 0·02 to 0·04, p<0·00001, 36 trials, 16419 participants), pneumonia (RD 0·0032; 95% CI 0·0003 to 0·0060, p=0·03, 31 trials, 15001 participants) and influenza (RD 0·0078; 95% CI 0·0031, 0·0126; p=0·001, 5 trials, 16395 participants) after smTKI exposure. No significantly increased risk was found for other respiratory complications. Interpretation SmTKI increases risk of URTI, pneumonia and influenza compared with placebo or conventional agents. The risk of any pulmonary adverse event with smTKI is low. Funding Nil

Suggested Citation

Khoo, Jun Keng and Barnes, Hayley and Key, Seraphina and Glaspole, Ian N. and Ostor, Andrew, Pulmonary Adverse Events of Small Molecule Tyrosine Kinase Inhibitors: Meta-Analysis and Systematic Review (November 3, 2019). Available at SSRN: https://ssrn.com/abstract=3346510 or http://dx.doi.org/10.2139/ssrn.3346510

Jun Keng Khoo

Alfred Hospital

Melbourne
Australia

Hayley Barnes

Alfred Hospital

Melbourne
Australia

Seraphina Key

Monash University - Central Clinical School

Clayton
Australia

Ian N. Glaspole

Alfred Hospital

Melbourne
Australia

Monash University - Central Clinical School

Clayton
Australia

Andrew Ostor (Contact Author)

Monash University - Central Clinical School ( email )

Clayton
Australia

Cabrini Medical Centre ( email )

Malvern
Australia

Click here to go to TheLancet.com

Paper statistics

Abstract Views
241
Downloads
25